Compare OSPN & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | AQST |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.6M | 504.0M |
| IPO Year | 2000 | 2007 |
| Metric | OSPN | AQST |
|---|---|---|
| Price | $14.55 | $4.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $16.67 | $9.00 |
| AVG Volume (30 Days) | 506.0K | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | ★ 28.77 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $243,180,000.00 | $67,430,000.00 |
| Revenue This Year | $3.22 | $10.08 |
| Revenue Next Year | $3.16 | $49.60 |
| P/E Ratio | $47.77 | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $10.07 | $2.94 |
| 52 Week High | $18.13 | $7.55 |
| Indicator | OSPN | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 64.92 | 54.50 |
| Support Level | $12.09 | $3.95 |
| Resistance Level | $16.17 | $4.38 |
| Average True Range (ATR) | 0.55 | 0.15 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 49.78 | 78.89 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.